30 June 2022
Camellia Plc
(the "Company" or the "Group")
Associate company update
Camellia Plc (CAM.L) announces that its 37.4% owned associate company, BF&M Limited ("BF&M"), a listed Bermudian insurance business, yesterday issued a statement that in order to maximise shareholder value, it has initiated a review of strategic alternatives for the business. This may include a range of outcomes for BF&M, including, inter alia, the sale of BF&M. The full text of BF&M's announcement can be found in Appendix 1 to this announcement.
There can be no guarantee as to the outcome of the BF&M strategic review. A further announcement will be made in due course as and when appropriate.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
Enquiries
Camellia Plc 01622 746655
Malcolm Perkins, Chairman
Susan Walker, Chief Financial Officer
Panmure Gordon 020 7886 2500
Nominated Adviser and Broker
Emma Earl
Erik Anderson
Maitland/AMO
PR
William Clutterbuck 07785 292617
Appendix 1 BF&M announces Strategic Review
Hamilton, Bermuda. 29 June 2022- BF&M Limited (BF&M or the 'Company') (BSX:BFM) announced today that, following discussions with its principal 37.4% shareholder, the Board of Directors ( the 'Board') has initiated a review of strategic alternatives (the Strategic Review) to maximise shareholder value and which may include the sale of the Company.
The Board has established a special committee (Special Committee), chaired by Group Chairman and Chief Executive Officer John Wight and including Jennifer Reynolds and Anthony Joaquin, both independent directors, to oversee the Strategic Review. The Special Committee has retained Desjardins Capital Markets to assist it in this process.
John Wight stated: 'Throughout and beyond the Strategic Review process, BF&M will remain focused on enhancing corporate value by steadily carrying out business activities, delivering excellent customer service and executing on our long-term strategy.'
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.